symbol=IMGN IMMU Research Package: http://stock-callers.com/registration/?symbol=IMMU VNDA Research …
The stock's market cap is $610.36 million. Zacks' sales averages are a mean average based on a survey of research analysts that follow Vanda Pharmaceuticals. Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly …
As the Dow Jones struggles to reach positive territory, let me guide your attention to a stock by the name of Vanda Pharmaceuticals, Inc. stock symbol VNDA. Vanda Pharmaceuticals specializes in bio pharmaceutical product …
IXYS Corp. (IXYS) traded at $11.22 + 0.83 (7.94 pct) on 40,170 total stock volume. The company is -11.16 pct year-to-date, and -5.90 pct during the past four quarters. Vanda Pharmaceuticals Inc. (VNDA) traded at $10.17 + 0.68 (7.16 pct) on …
a sizeable “surprise factor” can lead to a large change in the stock’s price during the time immediately following the …
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)'s stock had its "buy" rating reiterated by research analysts at Jefferies Group in a report issued on Sunday. They presently have a $23.00 price target on the biopharmaceutical company's …
If the potential market for the drug does prove to be small, the stock’s price could fall as quickly as it rose. In the short-term, VNDA is overbought with a PowerRatings of 1 and the stock could be a short candidate over $15.03. ConnorsRSI …
Vanda Pharmaceuticals Inc. (VNDA) announced after the close Thursday that it has received FDA approval for Fanapt for maintenance treatment for schizophrenia in adults. The stock is now up 0.81 on 61K shares. Vanda Pharmaceuticals …
The most volatile biotech stock currently going is Vanda Pharmaceuticals (NASDAQ: VNDA). Vanda’s one-year annualized Beta is currently 4.47; this means that for every one percent move in the S&P, Vanda moves an average of 4.47 …
VNDA became a penny stock. I had once covered the company for awhile a couple ... NVS will still get a royalty on sales, but in an exclusive interview on CNBC's "Squawk on the Street" this morning, I asked the Swiss drugmaker's Chairman …